NZ625817B2 - Preparations containing amorphous emodepside - Google Patents

Abstract

Provided are preparations comprising amorphous emodepside in a polyvinylpyrrolidone matrix. The preparation may be a coprecipitate or a melt extrudate. The preparations may be useful against endoparasites in animals or humans.

Description

Preparations containing amorphous emodepside The invention relates to preparations comprising amorphous emodepside in a polyvinylpyrrolidone , pharmaceuticals comprising such preparations, and their use against endoparasites in animals or humans.

The cyclic depsipeptide emodepside, which has anthelmintic activity, is known from WO 93/19053. A variety of application forms have already been described, for example starch-based extrudates (WO 02/00202), or a solid dosage form with delayed release ( A2).

Kachi et al. (Jpn. J. Pharmacol. 77 (1998) 235-245) bes the amorphous and polymorphous crystalline forms of the ctadepsipeptide PF1022A.

Schütte (PhD thesis, Bonn 2004) describes “Untersuchungen zur Komplexierbarkeit von pharmazeutischen Wirkstoffen mit e durch Extrusion mit Hochamylosestärken” [Studies on the complexability of pharmaceutical active substances with amylose by extrusion with high-amylose starches]. Also described therein are emodepside extrudates in which starch was used as the base.

Emodepside is a sparingly soluble drug substance with poor permeability. The solubility in water in the range of pH 4 – 10 is 5 – 7 mg/l.

Said active substances frequently have poor ilability. There is therefore a need for emodepside ations with improved bioavailability.

It has now been found that amorphous emodepside in specific matrices has a better solubility in water and very good bioavailability in comparison with crystalline emodepside.

The invention relates to preparations comprising emodepside in amorphous form in a polyvinylpyrrolidone .

The invention furthermore relates to pharmaceuticals comprising such preparations.

The invention furthermore s to the use of the preparations according to the invention or of the pharmaceuticals comprising the preparations according to the invention for lling endoparasites in humans or s.

The invention furthermore relates to the use of the preparations according to the invention in the cture of a pharmaceutical composition. Preferably the composition is for controlling endoparasites in humans or animals. - 2 — The INN emodepside represents the compound with the atic name: cyclo[(R)—lactoyl-N— methyl-l-leucyl-(R)(p-morpholinophenyl)lactoyl-N-methyl-l-lcucyl-(R)-lactoy1—N-methyl-l- leucyl-(R)-3—(p-m0rpholin0phenyl)lactoyl-N-methyl-l-leucyl. Emodepside is described in W0 93/19053 and has the following formula: In principle, the ations according to the invention may comprise further active substances.

Depending on the structure, active substances can be t in stereoisomeric forms or as stereoisomer mixtures, for example as enantiomers or as a racemat. The active substance emodepside has a total of 8 chiral C atoms — 41 leucine units, 2 D—lactic acid units and 2 D-polylactic acid units.

However, the synthesis is anenatioselective, so that the tation process only generates the one enantiomer of PF1022A.

In the preparations ing to the invention, the emodepside is present in the amorphous state.

Amorphous means that the atoms are present in an unordered structure. In the case of a crystalline substance, or in crystalline zones, the atoms have both a short-range order and a long-range order.

Amorphous material, in contrast, only has a short—range order. The degree of llization of the active substance can be determined for example with the aid of dynamic differential calorimetry or x-ray diffractometry.

In the case of a metric measurement, it is the melting enthalpy, in other words the energy required for melting the crystals, that is measured. If the active substance is present in a tely ous state, no change in the endothermal enthalpy can be measured upon heating.

When using x-ray diffraction as the measuring method, it is the distances between the molecular chains which are measured. In the amorphous state, no regular distances exiSt, which results in a broad distribution and no clear peaks in the diffractogram.

Other possibilities of checking the amorphous state are density ement, x-ray diffraction, infrared spectroscopy and nuclear-resonance spectroscopy.

In the preparations according to the invention, a proportion of at least 50% by weight, preferably at least 70% by weight, especially preferably at least 80% by , very specially ably at least 90% by weight, of the emodepside is present in the amorphous state, the percentages being based on the total amount of emodepside.

In case of doubt, the ous emodepside content is determined by dynamic differential calorimetry.

The side is present in a polyvinylpyrrolidone matrix. Suitable “polyvinylpyrrolidones” are not only pure polyvinylpyrrolidones, but also their derivatives or mixtures of polyvinylpyrrolidones and polyvinylpyrrolidone derivatives.

Polyvinylpyrrolidones (povidones, PVPs) are commercially available hydrophilic polymers.

Various types of PVPs are able. PVPs with a relatively low molecular weight are conventionally employed as binders for tablets. In an aqueous medium, PVPs will swell and erode.

The polyvinylpyrrolidones or polyvinylpyrrolidone derivatives employed are preferably water— soluble. As a rule, they are linear, osslinked polyvinylpyrrolidones or polyvinylpyrrolidone derivatives.

The pure polyvinylpyrrolidones or polyvinylpyrrolidone derivatives employed in accordance with the ion y have a K value in the range of from 12 to 90, preferably 12 to 30.

The K value of the polyvinylpyrrolidones or polyvinylpyrrolidone derivatives is in a relationship with the viscosity and the molecular weight and can be determined by methods known per se. In case of doubt, the information on the K value found in the European Pharrnacopeia (Ph. Eur.) will be used.

Preferably, the pure polyvinylpyrrolidones have a K value of from 12 to 90, especially preferably from 12 to 25, very especially preferably from 12 to 17.

The polyvinylpyrrolidone derivatives are usually polyvinylpyrrolidone mers. In the case of the polyvinylpyrrolidone copolymers, polymers with a K value of 25-30 will preferably be used. - 4 — A preferred polyvinylpyrrolidone derivative is copovidone (for e Kollidon VA 64 from BASF). This is a vinylpyrrolidone/vinyl acetate copolymer in the ratio of 6:4 with a K value of approximately 30.

The preparation usually comprises at least 50% by weight, preferably at least 66% by weight, especially preferably 75% by , of polyvinylpyrrolidone.

Details on the abovementioned polyvinylpyrrolidones, polyvinylpyrrolidone derivatives and certain mixtures can be found in the ing book: V. Biihler, “Kollidon, Polyvinylpyrrolidone for the pharmaceutical industry”, 9th revised edition, BASF Pharma Ingredients, Germany, 2008.

At least two methods which are known per se exist for preparing the preparations according to the invention: solvent coprecipitation and melt extrusion.

In the case of t ipitation, emodepside together with the polymer is dissolved in the solvent, and the solvent is subsequently removed again, for example with reduced pressure and, optionally, elevated temperature. Suitable are solvents and solvent mixtures in which both the active substance and the polymer will dissolve. nces which are le for the preparations according to the invention are, for example, ethanol, acetonitrile, methanol, acetone and isopropanol or their es. The polymers employed in solvent coprecipitation are preferably polyvinylpyrrolidones with a K value of between 12 and 30, preferably 12 and 17, since it is easier to remove the solvent from those than from polyvinylpyrrolidones with a greater K value.

In the case of melt extrusion, the active substance is mixed with the polymer and transferred into an extruder. The extrusion temperature is below the melting point of the active substance. In the case of emodepside, the extrusion may take place between 80 and 190°C, preferably between 140 and l 80°C.

The melting point of the dynamically most stable emodepside ation is 192°C.

During the extrusion, emodepside ves in the polymer, and upon cooling it precipitates in the amorphous state. In general, preferred polyvinylpyrrolidones are those with a low glass transition temperature so as not to pose a risk to the stability of the active substance. In on, it must not be too low so as to ensure a certain degree of storage stability. Polymers which can be recommended are those with a glass transition temperature of at least 80°C, but markedly below the g point of emodepside, that is 80°C to 160°C, preferably 80°C to 140°C. The glass transition temperature of polyvinylpyrrolidone with a K value of 12 is approximately 90°C and with a K value of 25 approximately 155°C.

In the case of melt extrusion, it is possible to additionally add surfactants to the system. Surfactants which are suitable in principle are customary pharmaceutically acceptable pulverulent or liquid surfactants. Examples which may be mentioned are: polyoxyethylene glycerol ricinoleate 35, macrogol glycerol hydroxystearate 40, but also bile salts, lecithins and non-ionic surfactants such as sodium dodecyl sulphate. Other examples which may be mentioned are the polysorbate 20, 60 or 80 and poloxamers.

The preparations ing to the ion may be used directly per se, or else they are processed with addition of other adjuvants. In this context, they are present in the form of granules or in the form of a powder, preferably following a grinding step, both for direct use and for processing.

“Pharmaceuticals” for the purpose of the present invention may be the preparations themselves or else compositions which, in addition to the preparations, also comprise pharmaceutically acceptable adjuvants.

Oral pharmaceutical forms which are suitable are s, granules, suspensions, capsules or tablets, with tablets being preferred.

Possible adjuvants which may be mentioned are: , ts, lubricants, disintegrants, surfactants and the like.

Fillers which are suitable are fillers which are conventionally used for solid preparations (for example tablets), such as, for example, pharmaceutically employed starches, for example potato, wheat, maize and rice starch, various mono- and disaccharides, for example glucose, e and sucrose, and the sugar alcohols mannitol and sorbitol. Colloidal carbonates such as calcium carbonates, hydrogencarbonates, sodium chloride, aluminium oxides, silicas, clays and ates (especially calcium phosphates) may also be employed, it also being possible for ent fillers to be ed with each other. Fillers having additional dry-binding properties which are used are celluloses, ably microcrystalline ose. The total amount of filler(s) is usually 5-80% 3O (In/m), preferably 10 to 70% (In/m), especially preferably 20 to 50% .

Furthermore, the solid pharmaceutical preparations according to the invention may, besides the active substance(s) and other abovementioned constituents, additionally se further adjuvants. Glidants which are used are, for example, colloidal silica, hydrogenated vegetable oils, stearic acid, talc or their mixtures, optionally in amounts of from usually 0.1 to 2%, preferably 0.5-1.5% (m/m). ants, such as, for example, magnesium stearate, are optionally t in amounts of from usually 0.3-2% (m/m), preferably 0.5 to 1.5 (m/m). In addition, it is possible to add, to the formula, egrants such as, for example, croscarmellose sodium in s of usually 1-10% (m/m). However, higher concentrations such as 10-40% may also be used. tants, for example sodium dodecylsulphate, usually 0.1-1% (In/m), preferably 0.5-l% (m/m), be incorporated are the non-ionic may be added to improve wetting. Further tants which may surfactants polyoxyethylene glycerol ricinoleate 35, macrogol glycerol hydroxystearate 40, ylated sorbitan monooleate, sorbitan monostearate, ethyl alcohol, glycerol monostearate, polyoxyethyl stearate and alkylphenol propyl glycol ether, the ampholytic surfactants disodium N- lauryl-B-iminodipropionate and lecithin, and the anionic surfactants sodium lauryl sulphate, fatty alcohol ether sulphate and mono/dialkyl polyglycol ether orthophosphoric ester monoethanolamine salts.

To improve the palatability, aromas and/or flavourings may furthermore be added to the formula.

The preparations according to the invention can be prepared for example by mixing or granulating the components and then compressing the product to give tablets. Preferred in this context is the direct tableting of the starting materials, that is to say that all starting materials are mixed and that the mixture is directly compressed to give tablets, without further s steps such as granulation or the like.

The preparations according to the invention, or the pharmaceuticals according to the invention, are suitable for lling pathogenic endoparasites which are found in humans and in animal keeping and animal ng in ock, breeding stock, 200 animals, laboratory animals, experimental animals and pets, while having favourable toxicity to warm-blooded species. They can be employed against all or individual developmental stages of the pests and against resistant and normally-sensitive rasite isolates. By controlling the pathogenic rasites, it is intended to reduce disease, deaths and reduced performance (for example in the production of meat, milk, wool, hides, eggs, honey and the like), so that more economical, simpler and healthier animal keeping is made possible by employing the active substances. The pathogenic endoparasites e helrninths such as Platyhelmintha (in particular Monogenea, a and Trematoda), Nematoda, Pentastoma and ocephala. Examples which may be mentioned are: Monogenea: for e: Gyrodactylus spp., Dactylogyrus spp., Polystoma spp..

Cestoda: From the order Pseudophyllidea, for e: Diphyllobothrium spp., Spirometra spp., Schistocephalus spp., Ligula spp., Bothridium spp., Diphlogonoporus spp..

From the order Cyclophyllida, for example: Mesocestoides spp., cephala spp., Paranoplo- cephala Stilesia spp., Moniezia spp., Thysanosoma spp., Thysaniezia spp., Avitellina spp., spp., Cittotaenia spp., Andyra spp., Bertiella spp., Taenia spp., Echinococcus spp., Hydatigera spp., Davainea spp., Raillietina spp., Hymenolepis spp., Echinolepis spp., Echinocotyle spp., Diorchis spp., Dipylidium spp., Joyeuxiella spp., Diplopylidium spp..

PCT/EP2012/O75909 Trematoda: from the class Digenea, for example: Diplostomum spp., Posthodiplostomum spp., Schistosoma spp., bilharzia spp., Ornithobilharzia spp., Austrobilharzia spp., Gigantobilhar- Zia spp., Leucochloridium spp., Brachylaima spp., stoma spp., Echinoparyphium spp., Echi- nochasmus spp., Hypoderaeum spp., Fasciola spp., Fasciolides spp., Fasciolopsis spp., Cyclocoe- lum spp., Typhlocoelum spp., Paramphistomum spp., Calicophoron spp., Cotylophoron spp., Gi- gantocotyle spp., Fischoederius spp., Gastrothylacus spp., Notocotylus spp., Catatropis spp., Pla- is spp., Prosthogonimus spp., oelium spp., Eurytrema spp., Troglotrema spp., - nimus spp., Collyriclum spp., Nanophyetus spp., Opisthorchis spp., Clonorchis spp., Metorchis spp., Heterophyes spp., Metagonimus spp..

Nematoda: From the order Trichinellida, for example: Trichuris spp., Capillaria spp., Tri- chomosoides spp., Trichinella spp..

From the order hida, for example: Micronema spp., Strongyloides spp..

From the order Rhabditina, for example: Strongylus spp., Triodontophorus spp., Oesophagodontus ostomum spp., Cycloco- spp., Trichonema spp., Gyalocephalus spp., Cylindropharynx spp., cercus spp., Cylicostephanus spp., Oesophagostomum spp., Chabertia spp., Stephanurus spp., An- cylostoma spp., Uncinaria spp., Bunostomum spp., Globocephalus spp., Syngamus spp., Cyathosto- ma spp., rongylus spp., Dictyocaulus spp., Muellerius spp., Protostrongylus spp., Neostrongylus spp., Cystocaulus Parela— spp., Pneumostrongylus spp., Spicocaulus spp., Elaphostrongylus spp., ongylus spp., Crenosoma spp., Paracrenosoma spp., Angiostrongylus spp., Aelurostrongylus spp., Filaroides spp., Parafilaroides spp., Trichostrongylus spp., Haemonchus spp., Ostertagia spp., Marshallagia spp., Cooperia spp., dirus spp., Hyostrongylus spp., Obeliscoides spp., Amidostomum spp., Ollulanus spp..

From the order Spirurida, for example: Oxyuris spp., Enterobius spp., Passalurus spp., Syphacia spp., Aspiculuris spp., Heterakis spp.; Ascan's spp., Toxascaris spp., Toxocara spp., Baylisascaris spp., Parascaris spp., Anisakis spp., Ascaridia spp.; Gnathostoma spp., Physaloptera spp., Thelazia spp., onema spp., Habronema spp., Parabronema spp., Draschia spp., Dracunculus spp.; Stephanofilaria spp., Parafilaria spp., Setan'a spp., Loa spp., Dirofilaria spp., Litomosoides spp., Brugia spp., Wuchereria spp., Onchocerca spp..

Acanthocephala: From the order Oligacanthorhynchida, for example: Macracanthorhynchus spp., Prosthenorchjs spp.; from the order Polymorphida, for example: Filicollis spp.; from the order Monilifonnida, for example: formis spp..

From the order Echinorhynchida, for e: Acanthocephalus spp., Echinorhynchus spp., Leptorhynchoides spp..

Pentastoma: From the order Porocephalida, for e: Linguatula spp.. - 8 — In ance with a preferred embodiment, the preparations according to the invention, or the pharmaceuticals according to the invention, are employed for controlling heart worm, Dirofilaria immitis.

Animals may be fish, reptiles, birds or in particular mammals.

The livestock and breeding stock include mammals such as, for example, cattle, horses, sheep, pigs, goats, camels, water buffalo, monkeys, rabbits, fallow deer, reindeer, fur-bearing animals such as, for e, mink, chinchilla, racoon, birds such as, for example, ns, geese, turkeys, ducks, ostriches, fish such as trout, salmon, carp, perch, pikes, eels.

Laboratory animals and experimental animals include mice, rats, guinea pigs, golden hamsters, dogs and cats.

The pets include dogs and cats.

Preferred in accordance with the invention is the use in animals, but the use in humans is also possible in ple.

The application may be either prophylactic or else therapeutic.

The preparations according to the invention with ous emodepside have good bioavailability.

They show a high plasma level concentration and good data as s the area under the concentration-time curve of emodepside in the blood.

Examples 1. Coprecipitate prepared by solvent method When preparing a solvent coprecipitate, side and polyvinylpyrrolidone with a K value of 12, 17 or 25 are mixed and ved in ethanol or in a solvent mixture of acetone and isopropanol. After everything has dissolved, the solution is transferred to a sheet, and the solvent is stripped off at elevated temperature and reduced pressure in a vacuum drying oven. Thereafter, the ipitate thus obtained is scrapped off the sheet and ground. The powder thus ed may now be administered either directly, for example filled into capsules, or, after processing, in the form of tablets.

Coprecipitates ofthe following compositions were prepared, where the compositions were in each case converted to a theoretical total weight of 100 g of the coprecipitate. In each case three compositions with polyvinylpyrrolidone-12, -17 and -25 were ed for each example: Example 1: g Emodepside 75 g Polyvinylpyrrolidone-12, -17 or -25 Isopropanol/acetone 1:1 (until everything has dissolved) Example 2: 50 g side 50 g nylpyrrolidone—l2, -17 or -25 Isopropanol/acetone 1:1 (until everything has dissolved) Example 3: 9.09 g Emodepside 90.91 g Polyvinylpyrrolidone-12, -17 or -25 Isopropanol/acetone 1:1 (until everything has dissolved) Example 4: 25 g Emodepside 75 g nylpyrrolidone—IZ, -17 or -25 Ethanol (until everything has dissolved) Example 5: 2O 33.33 g Emodepside 66.67 g nylpyrrolidone—12, -17 or -25 Ethanol (until everything has dissolved) Example 6: 9.09 g Emodepside 90.91 g Polyvinylpyrrolidone-IZ, -17 or -25 Ethanol (until everything has dissolved) 2. Tablet formulation: When the coprecipitate is processed to give tablets, it is mixed with the tableting aids microcrystalline cellulose, croscarmellose sodium, highly-dispersed silica, sodium dodecyl sulphate and magnesium stearate and the mixture is compressed to give tablets.

The following tablet formulation may be ned by way of example: Example 7: (a 100 g batch is composed of) 21.3 g Solvent coprecipitate as per Example 1 with polyvinylpyrrolidone-12 32 g Microcrystalline ose 42.6 g Croscarmellose sodium PCT/EP2012/O75909 0.8 g Sodium dodecyl sulphate 1.6 g Highly-dispersed silica 1.6 g Magnesium te. 3. Cowpitatiprepired bmelt extrusion In the case of the preparation which is ed by melt extrusion (extruded coprecipitate), emodepside and the polyvinylpyrrolidone copolyrner idone, for example Kollidon VA 64 from BASF) are mixed and transferred into the extruder. If required, a surfactant, for example, polyoxyethylene glycerol ricinoleate 35, can be introduced via liquid metering. This mixture is extruded at 160°C. Extrusion at 180°C is also possible. The ing emodepside/polyvinylpyrrolidone extrudates are cooled and ground. Again, here the powder may be administered as such or processed to give tablets.

Extruded coprecipitates of the following compositions were prepared, while the compositions were in each case converted to a theoretical total weight of 100 g of the extruded coprecipitate: Example 8: g Emodepside 70 g Copovidone 10 g yethylene glycerol ricinoleate 35 Example 9: 9.09 g Emodepside 80.91 g Copovidone 10 g Polyoxyethylene glycerol ricinoleate 35 Example 10: g Emodepside 80 g Copovidone 4. Tablet formulation The preparation which is obtained by melt extrusion, too, can be processed in the same manner to give tablets. An example which may be mentioned is the following tablet e: Example 11 (a 100 g batch is ed of): .3 g Extruded coprecipitate according to Example 8 .4 g Microcrystalline cellulose 40.5 g Croscarmellose sodium 0.8 g Sodium dodecyl sulphate 1.5 g Highly-dispersed silica 1.5 g ium stearate.

Biological example A. Study into the pharmacokinetics: The tablets of Example 7 (with 10 mg emodepside and a total weight of 187.5 mg) were administered to 10 dogs and the tablets of e 11 (with 10 mg emodepside and a total weight of 197.5 mg) were administered to 4 dogs, in each case orally. By way of comparison, an emodepside solketal solution (10% m/m) was administered to 4 dogs, in each case orally. For all ations, the dosage was 1 mg/kg body weight. Thereafter, blood was taken from the dogs at regular intervals up to 72 h after the application. The values of the maximum plasma level concentration Cmax were improved ly by using the active substance in the amorphous state: from 93 ug/l in the case of the emodepside solketal solution to 187 pg/l for tablets of Example 11 and 246 ug/l for tablets of Example 7. The AUC(0-24 h) values were d of 508 ug/l in the case of the solution 825 ug/l for the tablets of Example 11 and 1129 ug/l for the tablets of Example 7, respectively.

Patent

Claims (15)

Claims:

1. Preparation comprising side in amorphous form in a polyvinylpyrrolidone matrix.

2. Preparation according to Claim 1, additionally comprising a surfactant.

3. Preparation according to Claim 1, characterized in that it is a melt extrudate.

4. ation according to Claim 1, characterized in that it is a coprecipitate.

5. Pharmaceutical, comprising a preparation according to one of the ing claims and pharmaceutically acceptable adjuvants.

6. Preparation according to one of Claims 1 to 4 for use in the control of endoparasites in humans or animals.

7. Preparation according to Claim 6 for use in the control of Dirofilaria s.

8. Use of a preparation according to one of Claims 1 to 4 for the manufacture of a pharmaceutical.

9. Use according to Claim 8 for the manufacture of a pharmaceutical for controlling endoparasites in humans or animals.

10. Use of a preparation according to any one of claims 1 to 4, or a pharmaceutical according to claim 5 for lling tes in non-human animals.

11. Use according to Claim 9 or 10, where the endoparasites are Dirofilaria immitis.

12. A preparation according to claim 1, substantially as herein described or exemplified.

13. A pharmaceutical according to claim 5, substantially as herein described or exemplified.

14. A use according to claim 8, ntially as herein described or exemplified.

15. A use according to claim 10, substantially as herein described or exemplified.